[{"arm_notes": "", "treatment_id": null, "treatment_name": "Two tablets of TM5614 (120 mg) or placebo will be administered once daily; and the dose may be increased to 3 tablets at the physician's discretion. However; on Day 7; if bleeding symptoms or hepatic dysfunction are observed; or if increasing the dose to 3 tablets (180 mg) seems impossible; continue with 2 tablets (120 mg). The duration of study drug administration will be 14 days.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 1001, "treatment_name": "Plasminogen activator inhibitor-1 (pai-1)", "treatment_type": "Coagulation modifiers", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Two tablets of the investigational drug (120 mg) or placebo will be administered once daily; and the dose may be increased to 3 tablets at the physician's discretion. However; on Day 7; if bleeding symptoms or hepatic dysfunction are observed; or if increasing the dose to 3 tablets (180 mg) seems impossible; continue with 2 tablets (120 mg). The duration of study drug administration will be 14 days.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]